Primary Job Title CEO Primary Organization OncoSenX
Location Seattle, Washington, United States Regions Greater Seattle Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn
Matthew Scholz is the founder and Chief Executive Officer of Immusoft, a biotech start-up firm that is developing a breakthrough technology that will turn a patient’s B cells into miniature drug factories. Longer term, this technology has the potential to transform the landscape of biomedicine.
With a background in computer security, Matthew’s
initial concept for Immusoft’s core technology was based on using high speed cryptographic hardware to develop novel proteins to fight pathogens. In 2008, Matthew began conducting independent research in immunology and gene therapy and seeking input from some of the world’s top scientists. By 2009, he dramatically evolved the initial concept after conceiving how a research system developed by Nobel Laureate and former President of Caltech, David Baltimore, could be modified for a practical application: programming resting B cells to secrete therapeutic proteins. Matthew negotiated an exclusive license to the system, then developed and patented a way to improve its efficiency nearly seven-fold, thus making it clinically viable. This modified system is the core of Immusoft’s technology platform.
